At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...

In September 2025, the U.S. FDA launched a major enforcement campaign targeting direct-to-consumer (DTC) pharmaceutical advertising that misleads patients or downplays risks. Following a September ...

Jane Xia is an Assistant General Counsel Patents at Johnson & Johnson, specializing in patent strategy, portfolio development, licensing, and IP-related transactions. With over 13 years of experience, ...

Theodore is an intellectual Property attorney with 20+ years of experience protecting innovation and building patent portfolios, including preparing and executing strategic intellectual property plans ...

Rachel leads intellectual property and licensing at Arc. Previously, she held patent prosecution and licensing roles at both law firms and biotechnology companies. Rachel received a J.D. from Santa ...

Ann McCrackin stands at the intersection of law and technology, bringing over 25 years of experience as a patent attorney and a trailblazer in the integration of AI into legal practices. With a career ...

With deep expertise in electrical engineering and computer science, Aaron Gin, Ph.D., helps clients secure intellectual property rights for their innovative technologies. Dr. Gin prepares and ...

Dan is an experienced trial lawyer and life sciences litigator focusing on high-stakes patent, trade secret and commercial disputes. He litigates matters involving a wide variety of complex ...

Keith Jurek is Senior Patent Counsel with GRAIL Inc. He is primarily focused on building GRAIL's patent portfolio relating to the bioinformatics technology that contributes to the Galleri test and ...

•The FDA is undergoing a strategic reevaluation of its policies under new leadership, prompted by rapid advancements in science and technology. •Now is the time for FDA to pursue a proactive policy ...

Patient advocates say transparency will help the 340B program realign with its original intent of helping patients. Also, thoughts on supporting small molecules achieving big results. (735 words, 3 ...

Meetings between the Food and Drug Administration (FDA) and industry sponsors are critical to conducting effective and efficient drug development and bringing life-changing, innovative medicines to ...